U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H15N7O.2CH4O3S
Molecular Weight 501.537
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SAPANISERTIB DIMESYLATE

SMILES

CS(O)(=O)=O.CS(O)(=O)=O.CC(C)N1N=C(C2=C(N)N=CN=C12)C3=CC=C4OC(N)=NC4=C3

InChI

InChIKey=RIAVGZKNRXZPEG-UHFFFAOYSA-N
InChI=1S/C15H15N7O.2CH4O3S/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10;2*1-5(2,3)4/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19);2*1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H15N7O
Molecular Weight 309.3259
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sapanisertib is an oral dual inhibitor of mTORC1/mTORC2, discovered by Intellikine for the treatment of cancer. The drug is being tested in phase II of clinical trials for different cancers among which are sarcoma, hepatocellular carcinoma, etc. The drug is currently developed by Takeda with breast cancer, renal cancer and endometrial cancer being the main target indications.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.0 nM [IC50]
1.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
OverviewDrug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
mTOR Mediated Anti-Cancer Drug Discovery.
2009 Summer
ATP-competitive inhibitors of mTOR: an update.
2011
Patents

Sample Use Guides

Patients were receiving 15, 20 or 30 mg of sapanisertib orally on days 1, 8, 15 and 22.
Route of Administration: Oral
AML cell lines (OCI-AML3, U937, and MV4-11) were treated with different concentrations (6 nM, 18,5 nM, 56 nM, 166 nM, 500 nM) of sapanisertib for 72 hours and growth inhibition of cell lines was measured by Vi-Cell XR cell viability analyzer. AML samples were treated with 25 nM of the drug to study its anti-leukemic efficacy.
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:18:17 UTC 2023
Edited
by admin
on Sat Dec 16 06:18:17 UTC 2023
Record UNII
SB2601C5MF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAPANISERTIB DIMESYLATE
Common Name English
SAPANISERTIB DIMESILATE
WHO-DD  
Common Name English
Sapanisertib dimesilate [WHO-DD]
Common Name English
1H-PYRAZOLO(3,4-D)PYRIMIDIN-4-AMINE, 3-(2-AMINO-5-BENZOXAZOLYL)-1-(1-METHYLETHYL)-, METHANESULFONATE (1:2)
Systematic Name English
Code System Code Type Description
FDA UNII
SB2601C5MF
Created by admin on Sat Dec 16 06:18:17 UTC 2023 , Edited by admin on Sat Dec 16 06:18:17 UTC 2023
PRIMARY
PUBCHEM
126480210
Created by admin on Sat Dec 16 06:18:17 UTC 2023 , Edited by admin on Sat Dec 16 06:18:17 UTC 2023
PRIMARY
CAS
1422006-39-0
Created by admin on Sat Dec 16 06:18:17 UTC 2023 , Edited by admin on Sat Dec 16 06:18:17 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY